Key statistics
On Friday, Transgene SA (TRNG:DEU) closed at 1.02, 8.20% above its 52-week low of 0.939, set on Aug 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.00 |
---|---|
High | 1.06 |
Low | 0.983 |
Bid | 0.998 |
Offer | 1.09 |
Previous close | 1.02 |
Average volume | 1.08k |
---|---|
Shares outstanding | 132.29m |
Free float | 66.46m |
P/E (TTM) | -- |
Market cap | 137.32m EUR |
EPS (TTM) | -0.2227 EUR |
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Announcements
- Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
- Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase I/IIa dans les tumeurs solides résistantes
- Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
- Transgene nomme deux experts en oncologie pour conduire sa prochaine phase d'innovation
- Transgene et BioInvent présentent des données cliniques prometteuses de l’essai de Phase I/IIa du virus oncolytique BT-001 à l’ESMO 2024
- Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
- Transgene participera au HTID et à l’Investor Access Forum à Paris
- Transgene to Participate in HTID Conference and Investor Access Forum in Paris
- Transgene publie dans le JITC des données de preuve de concept préclinique du virus oncolytique TG6050
- Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC
More ▼